Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTS-412 in Treatment-refractory Solid Tumors
NCT07190833Phase 1Recruiting
- Sponsor
- Bionoxx
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of OTS-412 in solid tumor (7 cohorts), sponsored by Bionoxx. Primary endpoints: Recommended Phase 2 Dose at 28 days and Adverse Events at 180 days. Started Mar 2026; status: recruiting.
02
Drugs
OTS-412
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07190833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190833.